AAPL345.56-1.55 (-0.45%) ▼|ABBV287.93+1.54 (+0.54%) ▲|ABT102.98-0.12 (-0.12%) ▼|ACN244.04+8.88 (+3.77%) ▲|ADBE246.95-1.41 (-0.57%) ▼|AMAT414.42+18.49 (+4.67%) ▲|AMD569.40+9.14 (+1.63%) ▲|AMGN450.80+2.85 (+0.64%) ▲|AMT181.00-2.83 (-1.54%) ▼|AMZN252.19-0.91 (-0.36%) ▼|AVGO347.69+5.36 (+1.57%) ▲|AXP316.37+3.46 (+1.10%) ▲|BA166.64-1.54 (-0.92%) ▼|BAC50.89+0.21 (+0.41%) ▲|BKNG147.09-3.06 (-2.03%) ▼|BLK1,151.49+15.44 (+1.36%) ▲|BMY60.68-0.87 (-1.41%) ▼|BNY148.30+0.72 (+0.49%) ▲|BRK-B543.91+0.92 (+0.17%) ▲|C123.83+1.14 (+0.93%) ▲|CAT714.36+1.05 (+0.15%) ▲|CL91.56-0.61 (-0.66%) ▼|CMCSA21.67-0.18 (-0.80%) ▼|COF203.88+0.44 (+0.22%) ▲|COP149.96+2.00 (+1.35%) ▲|COST985.89-6.25 (-0.63%) ▼|CRM241.26+0.37 (+0.15%) ▲|CSCO109.94-1.45 (-1.30%) ▼|CVS90.24-0.89 (-0.98%) ▼|CVX231.21+2.98 (+1.31%) ▲|DE639.39-0.19 (-0.03%) ▼|DHR235.51+3.51 (+1.51%) ▲|DIS109.24-0.99 (-0.90%) ▼|DUK123.99-0.82 (-0.65%) ▼|EMR167.23+0.96 (+0.57%) ▲|FDX301.82-5.28 (-1.72%) ▼|GD354.55-0.34 (-0.10%) ▼|GE302.34+4.68 (+1.57%) ▲|GEV883.79-11.29 (-1.26%) ▼|GILD159.55+0.47 (+0.30%) ▲|GM81.30+0.76 (+0.94%) ▲|GOOG320.27+3.44 (+1.09%) ▲|GOOGL323.21+2.63 (+0.82%) ▲|GS921.54+9.77 (+1.07%) ▲|HD318.15-0.35 (-0.11%) ▼|HON219.63+0.82 (+0.37%) ▲|IBM251.93+1.68 (+0.67%) ▲|INTC94.37+0.63 (+0.67%) ▲|INTU328.74+0.29 (+0.09%) ▲|ISRG448.48+2.60 (+0.58%) ▲|JNJ271.63+2.90 (+1.08%) ▲|JPM339.54+3.75 (+1.12%) ▲|KO91.71+0.53 (+0.58%) ▲|LIN508.71+0.06 (+0.01%) ▲|LLY1,289.07+7.16 (+0.56%) ▲|LMT630.70+7.71 (+1.24%) ▲|LOW198.61+0.43 (+0.22%) ▲|LRCX253.16+12.31 (+5.11%) ▲|MA613.22+3.37 (+0.55%) ▲|MCD251.05+1.58 (+0.63%) ▲|MDLZ61.82-0.54 (-0.86%) ▼|MDT95.26+1.31 (+1.39%) ▲|META610.12-10.07 (-1.62%) ▼|MMM172.64+1.06 (+0.62%) ▲|MO73.21-0.28 (-0.38%) ▼|MRK140.47-1.35 (-0.95%) ▼|MS189.53+2.62 (+1.40%) ▲|MSFT526.45-4.88 (-0.92%) ▼|MU967.73+38.97 (+4.20%) ▲|NEE81.23-1.20 (-1.45%) ▼|NFLX61.60-0.93 (-1.48%) ▼|NKE37.24-0.33 (-0.87%) ▼|NOW149.79-5.00 (-3.23%) ▼|NVDA216.57-1.37 (-0.63%) ▼|ORCL129.61-0.93 (-0.71%) ▼|PEP132.65-0.85 (-0.64%) ▼|PFE29.31-0.49 (-1.64%) ▼|PG158.93-0.31 (-0.19%) ▼|PLTR193.43-5.31 (-2.67%) ▼|PM203.24+0.62 (+0.31%) ▲|QCOM180.64-3.53 (-1.92%) ▼|RTX197.45+2.85 (+1.46%) ▲|SBUX104.04+1.00 (+0.97%) ▲|SCHW88.30-1.00 (-1.12%) ▼|SO91.82-0.84 (-0.90%) ▼|SPG211.73-0.55 (-0.26%) ▼|T20.67-0.28 (-1.31%) ▼|TMO707.71+14.69 (+2.12%) ▲|TMUS145.50-1.33 (-0.91%) ▼|TSLA401.93-5.54 (-1.36%) ▼|TXN307.07-1.84 (-0.60%) ▼|UBER65.17-0.61 (-0.92%) ▼|UNH408.29-2.11 (-0.51%) ▼|UNP299.31-0.57 (-0.19%) ▼|UPS104.32-1.78 (-1.67%) ▼|USB59.35-0.39 (-0.65%) ▼|V402.18+0.32 (+0.08%) ▲|VZ43.19-0.75 (-1.70%) ▼|WFC83.94+1.28 (+1.55%) ▲|WMT119.15-0.18 (-0.15%) ▼|XOM182.72+2.81 (+1.56%) ▲|AAPL345.56-1.55 (-0.45%) ▼|ABBV287.93+1.54 (+0.54%) ▲|ABT102.98-0.12 (-0.12%) ▼|ACN244.04+8.88 (+3.77%) ▲|ADBE246.95-1.41 (-0.57%) ▼|AMAT414.42+18.49 (+4.67%) ▲|AMD569.40+9.14 (+1.63%) ▲|AMGN450.80+2.85 (+0.64%) ▲|AMT181.00-2.83 (-1.54%) ▼|AMZN252.19-0.91 (-0.36%) ▼|AVGO347.69+5.36 (+1.57%) ▲|AXP316.37+3.46 (+1.10%) ▲|BA166.64-1.54 (-0.92%) ▼|BAC50.89+0.21 (+0.41%) ▲|BKNG147.09-3.06 (-2.03%) ▼|BLK1,151.49+15.44 (+1.36%) ▲|BMY60.68-0.87 (-1.41%) ▼|BNY148.30+0.72 (+0.49%) ▲|BRK-B543.91+0.92 (+0.17%) ▲|C123.83+1.14 (+0.93%) ▲|CAT714.36+1.05 (+0.15%) ▲|CL91.56-0.61 (-0.66%) ▼|CMCSA21.67-0.18 (-0.80%) ▼|COF203.88+0.44 (+0.22%) ▲|COP149.96+2.00 (+1.35%) ▲|COST985.89-6.25 (-0.63%) ▼|CRM241.26+0.37 (+0.15%) ▲|CSCO109.94-1.45 (-1.30%) ▼|CVS90.24-0.89 (-0.98%) ▼|CVX231.21+2.98 (+1.31%) ▲|DE639.39-0.19 (-0.03%) ▼|DHR235.51+3.51 (+1.51%) ▲|DIS109.24-0.99 (-0.90%) ▼|DUK123.99-0.82 (-0.65%) ▼|EMR167.23+0.96 (+0.57%) ▲|FDX301.82-5.28 (-1.72%) ▼|GD354.55-0.34 (-0.10%) ▼|GE302.34+4.68 (+1.57%) ▲|GEV883.79-11.29 (-1.26%) ▼|GILD159.55+0.47 (+0.30%) ▲|GM81.30+0.76 (+0.94%) ▲|GOOG320.27+3.44 (+1.09%) ▲|GOOGL323.21+2.63 (+0.82%) ▲|GS921.54+9.77 (+1.07%) ▲|HD318.15-0.35 (-0.11%) ▼|HON219.63+0.82 (+0.37%) ▲|IBM251.93+1.68 (+0.67%) ▲|INTC94.37+0.63 (+0.67%) ▲|INTU328.74+0.29 (+0.09%) ▲|ISRG448.48+2.60 (+0.58%) ▲|JNJ271.63+2.90 (+1.08%) ▲|JPM339.54+3.75 (+1.12%) ▲|KO91.71+0.53 (+0.58%) ▲|LIN508.71+0.06 (+0.01%) ▲|LLY1,289.07+7.16 (+0.56%) ▲|LMT630.70+7.71 (+1.24%) ▲|LOW198.61+0.43 (+0.22%) ▲|LRCX253.16+12.31 (+5.11%) ▲|MA613.22+3.37 (+0.55%) ▲|MCD251.05+1.58 (+0.63%) ▲|MDLZ61.82-0.54 (-0.86%) ▼|MDT95.26+1.31 (+1.39%) ▲|META610.12-10.07 (-1.62%) ▼|MMM172.64+1.06 (+0.62%) ▲|MO73.21-0.28 (-0.38%) ▼|MRK140.47-1.35 (-0.95%) ▼|MS189.53+2.62 (+1.40%) ▲|MSFT526.45-4.88 (-0.92%) ▼|MU967.73+38.97 (+4.20%) ▲|NEE81.23-1.20 (-1.45%) ▼|NFLX61.60-0.93 (-1.48%) ▼|NKE37.24-0.33 (-0.87%) ▼|NOW149.79-5.00 (-3.23%) ▼|NVDA216.57-1.37 (-0.63%) ▼|ORCL129.61-0.93 (-0.71%) ▼|PEP132.65-0.85 (-0.64%) ▼|PFE29.31-0.49 (-1.64%) ▼|PG158.93-0.31 (-0.19%) ▼|PLTR193.43-5.31 (-2.67%) ▼|PM203.24+0.62 (+0.31%) ▲|QCOM180.64-3.53 (-1.92%) ▼|RTX197.45+2.85 (+1.46%) ▲|SBUX104.04+1.00 (+0.97%) ▲|SCHW88.30-1.00 (-1.12%) ▼|SO91.82-0.84 (-0.90%) ▼|SPG211.73-0.55 (-0.26%) ▼|T20.67-0.28 (-1.31%) ▼|TMO707.71+14.69 (+2.12%) ▲|TMUS145.50-1.33 (-0.91%) ▼|TSLA401.93-5.54 (-1.36%) ▼|TXN307.07-1.84 (-0.60%) ▼|UBER65.17-0.61 (-0.92%) ▼|UNH408.29-2.11 (-0.51%) ▼|UNP299.31-0.57 (-0.19%) ▼|UPS104.32-1.78 (-1.67%) ▼|USB59.35-0.39 (-0.65%) ▼|V402.18+0.32 (+0.08%) ▲|VZ43.19-0.75 (-1.70%) ▼|WFC83.94+1.28 (+1.55%) ▲|WMT119.15-0.18 (-0.15%) ▼|XOM182.72+2.81 (+1.56%) ▲|
16.6 C
New York
Wednesday, October 28, 2026

Tag: oral

newsFORsourcecompanycontentinformation1releasesmarket

Corteva Declares Quarterly Dividend

INDIANAPOLIS, Oct. 23, 2026 /PRNewswire/ -- Corteva, Inc. (NYSE: CTVA) today announced its Board of Directors, at its quarterly meeting, has authorized a common...

Alebund Pharmaceuticals Announces Poster Presentation by Partner R1 Therapeutics of Global Phase IIb Multi-Regional Clinical Trial Design for AP306 at ASN Kidney Week 2026

SHANGHAI, Oct. 23, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that its...

Carnyx Therapeutics Unveils Oral Sleep Candidate CNYX-005 with Preclinical Data Showing Increased NREM Sleep

Preclinical study shows 1.5- to 2-hour increase in total sleep time as Company advances toward clinical development and attracts Chris Brearley, M.D., as Chief...

Ascletis’ Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne

- With first patient dosed in Phase III clinical trial, Ascletis' strategic partner Sagimet Biosciences Inc. ("Sagimet") advances denifanstat (ASC40)'s U.S. registrational program, building...

HUYABIO International Announces HBI-8000 and Nivolumab Combination Reduces the Risk of Disease Progression by 27% in Patients with Advanced Melanoma in Phase 3 Trial

Oral HBI-8000 plus intravenous nivolumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with nivolumab alone, reducing the risk of...

Vylor Announces $3 Billion Share Repurchase Program

Reflects Company's Focus on Long-Term Value CreationJOHNSTON, Iowa, Oct. 22, 2026 /PRNewswire/ -- Vylor (NYSE: VYLR) today announced that its Board of Directors, at...

Tikva Allocell Selected to Present Preclinical CD19.SB9.CAR-EBVST Data at ACR Convergence 2026

Oral presentation will feature preclinical research evaluating Tikva's armored allogeneic CD19 CAR T-cell therapy as a potential lymphodepletion-free approach for systemic lupus erythematosusSINGAPORE, Oct....

Genomma Lab Internacional Announces Results for the Third Quarter 2026

MEXICO CITY, Oct. 21, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results...

ROLLINS, INC. REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS

ATLANTA, Oct. 21, 2026 /PRNewswire/ -- Rollins, Inc. (NYSE:ROL) ("Rollins" or the "Company"), a premier global consumer and commercial services company, reported unaudited financial...

Don’t Let Sour Candy Haunt Your Smile! The Minnesota Dental Association Shares Halloween Tips

MINNEAPOLIS, Oct. 21, 2026 /PRNewswire/ -- Candy may be part of Halloween, but cavities don't have to be! This Halloween, the Minnesota Dental Association...

Therakos Receives MDR Approval in Europe for Treating Immune-Related Adverse Events in Patients with Inadequate Response to Corticosteroids

DUBLIN, Oct. 22, 2026 /PRNewswire/ -- Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal photopheresis (ECP), announced...

Therakos Receives MDR Approval in Europe for Treating Immune-Related Adverse Events in Patients with Inadequate Response to Corticosteroids

DUBLIN, Oct. 21, 2026 /CNW/ -- Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal photopheresis (ECP), announced...

Therakos Receives MDR Approval in Europe for Treating Immune-Related Adverse Events in Patients with Inadequate Response to Corticosteroids

DUBLIN, Oct. 21, 2026 /PRNewswire/ -- Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal photopheresis (ECP), announced...

Kibow Therapeutics to Present Phase 2b Results for KT-301 in Stage 4 Chronic Kidney Disease at ASN Kidney Week 2026

Randomized, Double-Blind Phase 2b Data in 327 Patients, Plus New Mechanistic Research, to Be Presented October 23 in DenverEXTON, Pa., Oct. 21, 2026 /PRNewswire/...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsOral

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers